PHARMACY

Synergy Medical ranks on Canadian Business’ 2017 Profit 500

BY David Salazar

MONTREAL, Canada — Synergy Medical is among Canada’s fastest-growing companies, according to the latest installation of the Canadian Business Profit 500. The ranking, published in the Maclean’s October issue and on CanadianBusiness.com, ranks 500 Canadian businesses based on their five-year revenue growth. Synergy Medical made the 2017 Profit 500 with five-year revenue growth of 78%.

“It is never easy to earn a spot on the Profit 500, but this year’s applicant pool was the most competitive yet,” Profit 500 program manager Deborah Aarts said. “This year’s winners demonstrate the resilience, innovation and sheer management smarts it takes to build a thriving business today.”

The company, which launched in 2008, designs, manufactures and installs pharmacy automation systems aimed at improving pharmacy efficiency while improving patient adherence. Synergy Medical has installed more than 300 of its SynMed and SynMed Ultra systems in North America and Europe.

“It is an honor for Synergy Medical to be classed among the fastest growing Canadian companies, and to be given the Profit 500 designation.” Synergy Medical president and founder Jean Boutin said. “It is the unwavering dedication and sustained efforts of our team that has allowed Synergy Medical to provide market-leading automation solutions to pharmacies, and consequently to receive this recognition.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

IPC’s government relations team hits Capitol Hill

BY David Salazar

SUN PRAIRIE, Wisc. — The Independent Pharmacy Cooperative’s government relations team, alongside board members, recently took to the nation’s capital to discuss issues affecting independent pharmacy with legislators. The team scheduled meetings with more than 25 legislators from more than 10 states.

“This is a great opportunity for the IPC team to express our need for legislative support and to represent the needs of our members and their communities.” IPC SVP government relations Mark Kinney said. “It is crucial that we speak for our members and actively work to achieve legislative and public policy successes important to independent pharmacy.”

IPC has worked with other industry stakeholders to pass legislation related to community pharmacy, and has advocated around such issues as a legislative response to direct and indirect remuneration, or DIR, fees; implementing a valid professional dispensing fee; and PBM Enforcement Regulation, among others.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Mylan launches generic Copaxone in 2 dosage strengths

BY David Salazar

HERTFORDSHIRE, England, and PITTSBURGH — Just a day after it received approval from the Food and Drug Administration for its generic of Copaxone (glatiramer acetate injection) — both as a 40-mg/mL three-times-a-week treatment and as a 20-mg/ml once-daily injection, the company has launched the drug.

Mylan’s generic was approved with an indication to treat patients with relapsing forms of multiple sclerosis.

“Mylan has invested tens of millions of dollars over many years to bring this important medicine to market,” Mylan CEO Heather Bresch said Wednesday following the drug’s approval. “Providing patients, healthcare providers and caregivers with treatment options is very important when it comes to selecting the right therapy for relapsing forms of multiple sclerosis.”

Copaxone is the most-prescribed treatment for MS, with the 20-mg/ml dosage strength bringing in $700 million and the 40-mg/ml dosage strength bringing in $3.64 billion in the 12 months ended July 31, according to QuintilesIMS data.

The introduction of Mylan’s generic puts it in competition both with branded Copaxone, made by Teva, as well as Sandoz’s previously approved generic Glatopa, which is only available in the 20-mg/ml dosage strength.

As part of the launch, Mylan is introducing its MS Advocate patient support service program to help patients with an interactive mobile app, in-home injection training, 24/7 support, co-pay assistance and ongoing support from a MS-experienced nurse.

“Our commitment to the MS patient community extends beyond bringing generic versions of these products to market,” Bresch said. “Mylan also is offering comprehensive patient support services to help patients access therapy as quickly as possible and adhere to a treatment regimen that fits their needs.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?